How does KRAS mutation affect treatment options for Endometrial Cancer
KRAS Mutations and Endometrial Cancer Treatment
I appreciate your question about KRAS mutations in endometrial cancer. However, I need to be transparent with you: the medical guidelines I have access to focus primarily on KRAS mutations in colorectal, lung, and pancreatic cancers—not endometrial cancer specifically.
What I Can Tell You
Based on the available evidence, here's what's important to understand:
KRAS mutations are found in multiple cancer types, but the frequency and clinical significance vary considerably:
- Pancreatic cancer: ~90% of cases
- Colorectal cancer: ~40% of cases
- Lung cancer: ~25% of cases
- Endometrial cancer: The prevalence and treatment implications are less well-established in the guidelines I have access to
Why This Matters for Your Situation
According to NCCN Guidelines, when KRAS mutations are identified in cancers where they're well-studied (like colorectal cancer), they typically:
- Affect which targeted therapies may work (for example, KRAS mutations make certain EGFR inhibitors ineffective)
- Guide treatment planning to help oncologists select the most appropriate therapy options
- Provide prognostic information about how the cancer may behave
Questions to Ask Your Oncology Team
Since endometrial cancer-specific KRAS guidance isn't in my current resources, I'd recommend asking your healthcare team:
- "What is the significance of the KRAS mutation status in MY endometrial cancer?"
- "Does this mutation change which treatment options you would recommend for me?"
- "Are there any clinical trials specifically for endometrial cancer with KRAS mutations that I should know about?"
- "Should I have additional genetic testing to look for other mutations that might guide treatment?"
- "How does my KRAS status affect my prognosis and treatment planning?"
Next Steps
Your oncologist has access to:
- The most current NCCN Guidelines for Endometrial Cancer (which I don't have in my current resources)
- Specialized knowledge about how KRAS mutations specifically impact endometrial cancer treatment
- Information about emerging clinical trials for your specific mutation status
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated May 19, 2026. Informational only — not a substitute for your oncology team.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Related Services
Services that may help with treatment for Endometrial Cancer patients
Have your records handy? Add them to a private case for a deeper, personalized read →
More questions about Endometrial Cancer
- What factors affect prognosis for Endometrial Cancer
- How does chemotherapy for Endometrial Cancer affect my immune system
- What genetic mutations are commonly found in Endometrial Cancer
- My Endometrial Cancer has spread to my brain — what are my options
- What fertility preservation options exist before Endometrial Cancer treatment in young adults
- My Endometrial Cancer came back — what are my options now
- How will I know if my Endometrial Cancer treatment is working
- How quickly do I need to start treatment for Endometrial Cancer